Iranian Research Plan to Reduce Breast Cancer Cells – | Iranian and world news

“Investigating the Effects of Escherichia Gypsy Bacteria Tumorosidal Cardiac Cardi Cell and Breast Cancer Cell” Keyvan Majidzadeh’s Research Project Keivan Majidzade The Institute is a trusted research with the support of the National Iranian Science Foundation.

Majidzadeh, a physician and medical biotechnology specialist from the Iranian Pasteur Institute, explained: Breast cancer is the most common type of cancer in women. There are more than one million new breast cancer each year. The prevalence rate of this complication has been high in most developed regions of the world and the highest prevalence has been observed in North America.

“The cancer in the Middle East has been the most common malignancy among women,” she said. In Iran, the most common cancer among the female population is breast cancer. The prevalence rate of breast cancer among women has been between the ages of 5 and 5, indicating the age of this type of cancer in Iranian women.

The researcher said: “Therapeutic solutions in the treatment of cancer have failures that overshadow the satisfying success in the treatment of breast cancer.” Conventional methods of treating breast cancer such as surgery, chemotherapy and radiation are typically unable to treat and complete cancer.

“In addition, it has been found that chemotherapy and radiation can cause many side effects,” he said. These problems have promoted and directed new treatments. One of these solutions is the use of bacteria in the treatment of cancer.

“Given the increase in the rate of cancer and especially breast cancer in the women’s population, finding good treatment strategies that can control and improve this complication seems to be vital,” she said.

Majidzadeh emphasized: Research on promoting and enhancing the efficiency of current breast cancer treatments does not meet expectations and, on the other hand, the high rate of death rate of cancer patients in developing countries compared to developed countries shows the costly therapies being costly. Therefore, it is necessary to introduce new and more efficient treatment options to the field of treatment by increasing the scope of cancer research to new and promising sectors.

The researchers in this study have developed a non -pathogenic Escherichia -gypsy bacterium in a way that could produce cardiac peptides and green fluorescent protein (GFP) simultaneously in this bacterium and in oxygen deficiency conditions. These engineered bacteria using an oxygen -sensitive promoter (NIRB) are specifically activated in the tumor -deficiency medium and release the drug at the same place. This procedure allows the bacterium to reach the tumor both in place and specifically secrete the drug into the tumor.

He said: In this study, three cardiac peptides, LANP, VD and KP have anti -cancer properties. These peptides can inhibit the growth of cancer cells and increase cell death. Especially the VD peptide shows the strongest anti -cancer properties.

The researcher and researcher added: In this study, green fluorescent protein was used as a marker to track the accumulation of bacteria and gene expression inside the tumor. The results of this study showed that cardiac peptides secreted by engineered bacteria reduced the growth of MCF1 breast cancer cells at the laboratory level and increased apoptosis (planned cell death).

He also stated that in animal study, in mice with mammary tumors, the intravenous injection of engineered bacteria caused the accumulation of engineered bacteria at the tumor site. These bacteria expressed green fluorescent protein (GFP) in the low oxygen medium of the tumor, and treatment with these bacteria led to a decrease in tumor growth, decreased expression of tumor and angiogens growth markers, as well as increased survival rates. Also, a decrease in pre -inflammatory cytokines and increase in anti -inflammatory cytokines were observed.

At the end, Majidzadeh noted: The results of this study showed that engineered bacteria can be used as a device for delivering anti -cancer proteins to the tumor site. This will inhibit tumor growth and improve survival. The use of oxygen -sensitive promoters is a key feature in this purposeful method.

In short, this study shows that engineered bacteria with specific targeting of tumor and anti -cancer peptides under oxygen deficiency conditions can be considered as a promising therapeutic approach for the treatment of breast cancer.